Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial.

Dent R, Shao Z, Schmid P, Cortes J, Cescon DW, Saji S, Jung KH, Bachelot T, Wang S, Ramírez EM, Basaran G, Stradella A, Mathiba R, Chen SC, Shen K, Wéber Á, Battelli N, Niikura N, Luo T, Chae YS, Fischbach N, Garbaos G, Patera A, Zhao K, Vuković P, Maxwell MJ, Traina T, TROPION-Breast02 investigators

Open source

DOI: 10.1016/j.annonc.2026.03.008
Published: 2026 Aug
Container: Annals of oncology : official journal of the European Society for Medical Oncology
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.annonc.2026.03.008,
  title = {Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial.},
  author = {Dent R and Shao Z and Schmid P and Cortes J and Cescon DW and Saji S and Jung KH and Bachelot T and Wang S and Ramírez EM and Basaran G and Stradella A and Mathiba R and Chen SC and Shen K and Wéber Á and Battelli N and Niikura N and Luo T and Chae YS and Fischbach N and Garbaos G and Patera A and Zhao K and Vuković P and Maxwell MJ and Traina T and TROPION-Breast02 investigators},
  year = {2026},
  journal = {Annals of oncology : official journal of the European Society for Medical Oncology},
  doi = {10.1016/j.annonc.2026.03.008},
  url = {https://doi.org/10.1016/j.annonc.2026.03.008}
}

RIS

TY  - JOUR
TI  - Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial.
AU  - Dent R
AU  - Shao Z
AU  - Schmid P
AU  - Cortes J
AU  - Cescon DW
AU  - Saji S
AU  - Jung KH
AU  - Bachelot T
AU  - Wang S
AU  - Ramírez EM
AU  - Basaran G
AU  - Stradella A
AU  - Mathiba R
AU  - Chen SC
AU  - Shen K
AU  - Wéber Á
AU  - Battelli N
AU  - Niikura N
AU  - Luo T
AU  - Chae YS
AU  - Fischbach N
AU  - Garbaos G
AU  - Patera A
AU  - Zhao K
AU  - Vuković P
AU  - Maxwell MJ
AU  - Traina T
AU  - TROPION-Breast02 investigators
PY  - 2026
JO  - Annals of oncology : official journal of the European Society for Medical Oncology
DO  - 10.1016/j.annonc.2026.03.008
UR  - https://doi.org/10.1016/j.annonc.2026.03.008
ER  -

APA

R, D., Z, S., P, S., J, C., DW, C., S, S., KH, J., T, B., S, W., EM, R., G, B., A, S., R, M., SC, C., K, S., Á, W., N, B., N, N., T, L., YS, C., N, F., G, G., A, P., K, Z., P, V., MJ, M., T, T., & investigators, T. (2026). Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial.. Annals of oncology : official journal of the European Society for Medical Oncology. https://doi.org/10.1016/j.annonc.2026.03.008

Source records

pubmed · retrieved 2026-09-26T00:39:58.589Z